These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 28835439)

  • 21. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
    Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E
    PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
    Maragkos GA; Nelton EB; Richter S; Stippler M
    World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor VIII Inhibitor Bypassing Activity (FEIBA) Reversal for Apixaban and Rivaroxaban in Patients With Acute Intracranial and Nonintracranial Hemorrhage.
    Hunt AR; Coffeen SN; Shiltz DL; Ice C; Parker J
    Ann Pharmacother; 2021 Dec; 55(12):1455-1466. PubMed ID: 33843267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
    Lipari L; Yang S; Milligan B; Blunck J
    Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.
    Coleman CI; Antz M; Bowrin K; Evers T; Simard EP; Bonnemeier H; Cappato R
    Curr Med Res Opin; 2016 Dec; 32(12):2047-2053. PubMed ID: 27633045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and effectiveness of a prothrombin complex concentrate in approved and off-label indications.
    Marcos-Jubilar M; García Erce JA; Martínez-Calle N; Páramo JA; Martínez Virto A; Quintana-Díaz M
    Transfus Med; 2019 Aug; 29(4):268-274. PubMed ID: 31347218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Proietti M; Romanazzi I; Romiti GF; Farcomeni A; Lip GYH
    Stroke; 2018 Jan; 49(1):98-106. PubMed ID: 29167388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation.
    Hill NR; Sandler B; Bergrath E; Milenković D; Ashaye AO; Farooqui U; Cohen AT
    Clin Appl Thromb Hemost; 2020; 26():1076029619898764. PubMed ID: 31918558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage.
    Pasciolla S; Wojcik K; Kavi T; Green D; Shaikh H; Jankowitz B; Igneri LA
    J Thromb Thrombolysis; 2022 Jul; 54(1):74-81. PubMed ID: 34837144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK.
    Folkerts K; Broughton J; Sheikh U; Mckaig S
    J Med Econ; 2019 Nov; 22(11):1179-1191. PubMed ID: 31433687
    [No Abstract]   [Full Text] [Related]  

  • 33. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world.
    Aryal MR; Gosain R; Donato A; Yu H; Katel A; Bhandari Y; Dhital R; Kouides PA
    Blood Adv; 2019 Aug; 3(15):2381-2387. PubMed ID: 31405948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.
    Grandhi R; Newman WC; Zhang X; Harrison G; Moran C; Okonkwo DO; Ducruet AF
    World Neurosurg; 2015 Dec; 84(6):1956-61. PubMed ID: 26341438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
    Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
    Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    J Thromb Haemost; 2015 Dec; 13(12):2220-6. PubMed ID: 26447393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants.
    Dager WE; Roberts AJ; Nishijima DK
    Thromb Res; 2019 Jan; 173():71-76. PubMed ID: 30476716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
    Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
    Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries.
    Cooksey GE; Hamilton LA; McMillen JC; Griffard JH; Rowe AS
    Neurocrit Care; 2022 Oct; 37(2):471-478. PubMed ID: 35624388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism.
    Bott-Kitslaar DM; McBane RD; Casanegra AI; Houghton DE; Froehling DA; Vlazny DT; Ashrani AA; Hodge DO; Vargas ER; Bartlett MA; Saadiq RA; Daniels PR; Shields RC; Lenz CJ; Lang TR; Wysokinski WE
    Mayo Clin Proc; 2019 Jul; 94(7):1242-1252. PubMed ID: 30737059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.